Aldeyra Therapeutics, Inc.

ALDX

Aldeyra Therapeutics, Inc.

ALDX

Insider Sentiment (TTM):

Last Purchase:2026-06-03Last Sale:2025-08-11Shares Purchased (TTM):327,500Shares Sold (TTM):22,073

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:35,723,784Shares Outstanding:60,319,289Institutional Ownership Pct.:59.22%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Aldeyra Therapeutics, Inc. (ALDX) — SEC Financial Statements & Analysis

Aldeyra Therapeutics, Inc. (ALDX) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Available For Sale Securities Debt Securities Curr…	-	0	16	41	40	47	45	49	31	0	0	0
Prepaid Expense And Other Assets Current	1	2	2	3	3	3	4	5	8	5	4	4
Assets Current	66	72	77	85	93	104	117	126	141	148	147	155
Deferred Costs	-	0	0	0	0	0	0	-	-	0	-	-
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	1	0	0
Property Plant And Equipment Net	-	-	-	-	-	0	0	0	0	0	0	0
Assets	66	72	78	85	93	105	117	126	141	148	147	156
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	0	0	0	1	0	0	0	0	0	1	0	0
Accrued Liabilities Current	3	6	7	7	8	12	10	6	6	6	8	9
Long Term Debt Current	15	15	15	15	0	0	0	15	15	15	13	6
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Current	-	6	-	-	-	6	6	6	-	0	-	-
Long Term Debt Noncurrent	0	0	0	0	15	15	15	-	0	0	3	10
Deferred Long Term Liability Charges	6	-	6	6	6	0	0	0	6	6	-	-
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	-	-
Liabilities Current	24	28	28	30	14	19	17	28	22	22	22	16
Liabilities	24	28	29	30	30	34	32	28	28	29	24	26
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	530	528	527	525	524	521	519	517	516	514	512	511
Accumulated Other Comprehensive Income Loss Net Of…	-	0	0	-0	0	0	0	-0	-0	0	0	0
Retained Earnings Accumulated Deficit	-487	-484	-477	-470	-460	-450	-434	-419	-402	-394	-390	-381
Stockholders Equity	42	44	49	55	64	71	85	98	113	120	123	130
Liabilities And Stockholders Equity	66	72	78	85	93	105	117	126	141	148	147	156
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	15	15	15	15	15	15	15	15	15	15	15	15
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	60	60	60	60	60	60	60	59	59	59	59	59
Shares Outstanding	60	60	60	60	60	60	60	59	59	59	59	59

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.16%	5.78%	-	-	-	-	-	-	-	-	-	-
2025	22.58%	98.16%	121.66%	12.96%	-1.93%	1.35%	11.16%	7.71%	5.27%	-66.85%	-67.03%	-69.23%
2024	-7.13%	-17.34%	-9.26%	50.13%	58.76%	53.64%	-8.24%	-7.49%	-4.12%	28.77%	-57.14%	-57.73%
2023	-	-	-	-4.17%	-22.47%	-79.17%	14.48%	57.47%	39.37%	-15.06%	2.08%	1.56%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	2.72	2.58	2.72	2.86	6.49	5.59	6.80	4.55	6.50	6.64	6.81	9.96
Quick Ratio	2.67	2.52	2.64	2.77	6.30	5.44	6.57	4.36	6.14	6.42	6.63	9.72
Working Capital	41.95M	43.97M	48.98M	55.03M	78.44M	85.47M	99.57M	98.05M	119.17M	125.55M	125.59M	139.87M
Leverage & Debt
Debt to Equity	0.58	0.63	0.58	0.54	0.47	0.47	0.38	0.28	0.25	0.24	0.20	0.20
Interest Coverage TTM	-15.01	-18.51	-23.76	-28.00	-32.00	-31.21	-25.20	-21.22	-17.02	-20.66	-24.97	-29.34
Debt Ratio	0.37	0.39	0.37	0.35	0.32	0.32	0.27	0.22	0.20	0.19	0.16	0.17
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.45	-0.56	-0.72	-0.84	-0.96	-0.94	-0.75	-0.64	-0.51	-0.64	-0.77	-0.89
Free Cash Flow Per Share TTM	-0.43	-0.56	-0.67	-0.68	-0.76	-0.73	-0.52	-0.52	-0.52	-0.51	-0.71	-0.79
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-52.56%	-39.40%	-3.58%	33.67%	92.27%	48.77%	-1.96%	-27.26%	-50.69%	-39.47%	-29.57%	-21.27%
EPS Growth (1Y)	-52.90%	-39.98%	-4.53%	32.26%	90.75%	47.41%	-2.85%	-28.02%	-51.20%	-40.02%	-30.21%	-21.92%
Valuation Metrics
P/E TTM	-3.72	-9.19	-7.27	-4.54	-5.97	-5.31	-7.16	-5.19	-6.47	-5.51	-8.62	-9.48
P/B	2.42	7.03	6.37	4.16	5.41	4.18	3.77	2.00	1.71	1.73	3.20	3.80
Market Cap	101.94M	311.09M	313.86M	229.97M	344.35M	296.83M	320.87M	196.66M	194.29M	206.89M	394.05M	493.26M
Enterprise Value	52.24M	256.30M	269.72M	203.88M	309.10M	257.33M	268.03M	140.87M	107.00M	79.21M	266.84M	357.61M
Calculated Values
Free Cash Flow TTM	-25.99M	-33.35M	-40.08M	-41.04M	-45.71M	-43.21M	-30.67M	-30.72M	-30.85M	-30.33M	-42.06M	-46.61M
Net Debt	-49.70M	-54.79M	-44.14M	-26.09M	-35.25M	-39.50M	-52.84M	-55.79M	-87.29M	-127.68M	-127.22M	-135.65M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-03Purchase

Owner: Brady, Todd C

Title: President and CEO

Shares: 250,000

Price/Share: $1.67

Value: $417,500.00

Shares Owned: 1,721,298

Relationship: Director,Officer

Ownership: Direct

2026-03-19Purchase

Owner: Douglas, Richard

Title: -

Shares: 70,000

Price/Share: $1.40

Value: $98,000.00

Shares Owned: 195,000

Relationship: Director

Ownership: Direct

2026-03-18Purchase

Owner: Alfieri, Michael

Title: Principal Financial Officer

Shares: 5,000

Price/Share: $1.42

Value: $7,100.00

Shares Owned: 7,500

Relationship: Officer

Ownership: Direct

2025-08-13Purchase

Owner: Alfieri, Michael

Title: Principal Financial Officer

Shares: 2,500

Price/Share: $5.30

Value: $13,250.00

Shares Owned: 2,500

Relationship: Officer

Ownership: Direct

2025-08-11Sale

Owner: Machatha, Stephen

Title: Chief Development Officer

Shares: 22,073

Price/Share: $5.15

Value: $113,675.95

Shares Owned: 221,799

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-03	Brady, Todd C	Director,Officer	President and CEO	Direct	Purchase	250,000	1.67	$417,500.00	1,721,298	4
2026-03-19	Douglas, Richard	Director	-	Direct	Purchase	70,000	1.40	$98,000.00	195,000	4
2026-03-18	Alfieri, Michael	Officer	Principal Financial Officer	Direct	Purchase	5,000	1.42	$7,100.00	7,500	4
2025-08-13	Alfieri, Michael	Officer	Principal Financial Officer	Direct	Purchase	2,500	5.30	$13,250.00	2,500	4
2025-08-11	Machatha, Stephen	Officer	Chief Development Officer	Direct	Sale	22,073	5.15	$113,675.95	221,799	4
2025-04-03	Perceptive, Life Sciences…	TenPercentOwner	-	Indirect	Sale	3,400,000	1.42	$4,828,000.00	5,875,851	4
2024-08-12	Machatha, Stephen	Officer	Chief Development Officer	Direct	Sale	16,041	4.74	$76,034.34	236,771	4
2024-08-12	Greenberg, Bruce	Officer	See Remarks	Direct	Sale	10,834	4.74	$51,353.16	126,382	4
2024-04-05	Edelman, Joseph, Percepti…	TenPercentOwner	-	Indirect	Purchase	37,712	4.74	$178,754.88	9,275,851	4
2024-04-03	Perceptive, Life Sciences…	TenPercentOwner	-	Indirect	Purchase	309,847	4.09	$1,267,274.23	9,097,858	4
2024-03-12	Machatha, Stephen	Officer	Chief Development Officer	Direct	Sale	11,537	3.16	$36,456.92	243,495	4
2024-03-12	Brady, Todd C	Director,Officer	President and CEO	Direct	Sale	85,324	3.05	$260,238.20	1,471,298	4
2024-03-12	Machatha, Stephen	Officer	Chief Development Officer	Direct	Sale	11,537	3.16	$36,456.92	252,812	4/A
2024-03-11	Greenberg, Bruce	Officer	See Remarks	Direct	Sale	13,201	3.41	$45,015.41	130,154	4/A
2024-03-11	Greenberg, Bruce	Officer	See Remarks	Direct	Sale	13,201	3.41	$45,015.41	120,699	4
2023-10-18	Perceptive, Life Sciences…	TenPercentOwner	-	Indirect	Sale	306,499	1.74	$533,308.26	8,593,586	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

59.22%

Inst. Shares: 35,723,784

Shares Outstanding: 60,319,289

2025-12-31

62.78%

Inst. Shares: 37,702,404

Shares Outstanding: 60,056,557

2025-09-30

63.45%

Inst. Shares: 38,149,687

Shares Outstanding: 60,126,850

2025-06-30

56.19%

Inst. Shares: 33,738,724

Shares Outstanding: 60,045,530

2025-03-31

62.25%

Inst. Shares: 37,279,045

Shares Outstanding: 59,887,277

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	35,723,784	60,319,289	59.22%
2025-12-31	37,702,404	60,056,557	62.78%
2025-09-30	38,149,687	60,126,850	63.45%
2025-06-30	33,738,724	60,045,530	56.19%
2025-03-31	37,279,045	59,887,277	62.25%
2024-12-31	36,799,863	59,484,794	61.86%
2024-09-30	35,980,700	59,530,113	60.44%
2024-06-30	34,713,042	59,414,489	58.43%
2024-03-31	33,865,886	59,414,489	57.00%
2023-12-31	33,991,772	58,943,205	57.67%
2023-09-30	36,833,698	58,990,189	62.44%
2023-06-30	37,920,287	58,791,920	64.50%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Aldeyra Therapeutics, Inc. (ALDX) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.